Neuropathic Pain, Spinal Cord Injuries
Conditions
Keywords
Pregabalin, Neuropathic pain, At-level neuropathic pain, Non-evoked neuropathic pain, Evoked neuropathic pain, Sub-acute spinal cord injury
Brief summary
This study is a phase IV clinical trial with the objective of evaluating whether pain relief associated with pregabalin for at-level non-evoked and evoked neuropathic pain is more efficient during the early rather than late subacute phase of spinal cord injury.
Interventions
DRUGPregabalin
Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
DRUGPlacebo
150mg BID p.o.
Sponsors
Julian Taylor Green
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Comprehension of clinical trial and signed informed consent before initiation. * Male or female adults, age 18 to 70. * Clinical history of neuropathic pain secondary to SCI * Patients with an AIS of A, B, C or D according to the American Spinal Cord Injury Association (ASIA) Impairment Scale. * Persistent neuropathic pain from 1 month up to 6 months after spinal cord injury. * Non-evoked at-level pain with ≥ 2 intensity measured with the numerical rating scale (0-10). * Non-evoked/evoked at-level pain corresponding to the area of sensory alteration, and within the three dermatomes below the neurological level of the spinal cord injury. * Formal acceptance of disponibility for all programmed clinical trial visits and other protocol requisites. * Females of child bearing age must demonstrate a negative pregnancy test (performed on screening and subsequent follow up visits) and use a reliable birth control method including abstinence of sexual activity throughout the duration of the study and for at last 28 days after termination of the clinical trial.
Exclusion criteria
* Previous or actual use of gabapentin. * Creatinine clearance level \<60 ml/min. * Neuropathic pain unrelated to spinal cord injury. * Lactose intolerance, Lapp lactase insufficiency or glucose malabsorption * Platelet count \< 100x103/µl. * White blood cell count \<2.5 x103/µl. * Neutrophil count \<1.5 x103/µl. * Planned surgery during the clinical trial. * Patients with peripheral neuropathic pain. * Previous history of malignant melanoma. * History of malignant tumors, except for in situ uterine cervix carcinoma, in situ basocellular or spinocellular cutaneous carcinomas, superficial bladder tumors (Ta and Tis) with a complete treatment response up to 10 years. Patients with history of lymphoma or breast cancer will be allowed to participate in the trial if a complete treatment response has been observed up to 20 years. * Chronic or active infection requiring a systemic therapy, chronic kidney infections, chronic lung infections with bronchiectasias, Mycobacterium tuberculosis infection, active Hepatitis B or C. Diagnosis of latent TB confection should be performed according to the local guidelines. * Severe heart diseases such as unstable angina, cardiopathy during the first 6 months after a myocardial infarction, grade III or IV of the New York Heart Association scale for congestive heart failure. * Unknown kidney, liver, gastrointestinal, endocrine, lung, hematological, neurological or psychiatric comorbidities. * Subjects administered with an experimental or non-commercial drug during the 4 weeks prior to the trial. * Patients participating in other clinical studies. * Patients that are not competent for completing required tasks (eg. alcohol or drug related problems or psychiatric disorders). * Subjects unable to be examined with radiological MRI exploration due to contraindications. * Pregnancy or breastfeeding. * Any other patient condition that is deemed unsuitable for subject inclusion in the trial according to the research team.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily at-level non-evoked pain intensity measured with the numerical rating scale (0-10) expressed as the mean 7-day pain intensity | — |
Secondary
| Measure | Time frame |
|---|---|
| Weekly evaluation of at-level neuropathic pain symptoms using the Neuropathic Pain Symptoms Inventory (NPSI) | — |
| Weekly evaluation of at-level neuropathic pain intensity and interference using the Brief Pain Inventory (BPI) | — |
| Weekly evaluation of the change in at-level non-evoked neuropathic pain using the Patient Global Impression Change (PGIC) | — |
| Weekly evaluation of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) | — |
| Weekly evaluation of spasm frequency below the spinal cord injury using the Penn questionnaire | — |
| Weekly below-level non-evoked pain intensity measured with the numerical rating scale (0-10) | — |
| Serum TNF-R1 level | — |
| Weekly at-level non-evoked pain intensity measured with the numerical rating scale (0-10) 28 days after the termination of the clinical trial | — |
| Number of Paracetamol tablets used as rescue medication during the week | — |
| Prevalence and type of adverse events in patients treated with pregabalin | — |
| Unblinding testing: patient and investigator will be asked for the treatment they think to have received. Reasons for their judgement (efficacy and safety) will also be asked. | — |
| Measurement of the amplitude of cold and heat sensory evoked potentials (Cz-Fz) studied above (C4) and at-level of the SCI | — |
Countries
Spain
Contacts
Primary ContactJulian Taylor Green
Outcome results
None listed